Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update

Résumé détaillé

LOS ANGELES, Nov. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on…

LOS ANGELES, Nov. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2026, and provided a corporate update.

"We continue to advance toward our most important near-term objective: initiating the Phase 3 superiority study of AP-SA02," said Armata's Dr. Deborah Birx, Chief Executive Officer. "We have progressed from planning to establishing the operational infrastructure needed to execute a large, pivotal clinical study. Our manufacturing capabilities are well established, critical clinical trial preparations are progressing, and we continue to work closely with the U.S. Food and Drug Administration ("FDA") to finalize the study design.

"We believe the FDA's recent Breakthrough Therapy designation further underscores AP-SA02's clinical potential. We also appreciate the continued financial support of the U.S. Department of War ("DoW"), which comes at an important time as we prepare for this next critical stage of clinical development. We believe AP-SA02 has the potential to make a meaningful difference in patient care and, more broadly, provide a foundation for expanding our bacteriophage technology into additional indications. We are excited about the opportunity ahead and remain firmly focused on successfully executing our Phase 3 program," concluded Dr. Birx.

Armata continued to make significant progress in clinical, regulatory, manufacturing, and operational preparations for the planned pivotal Phase 3 superiority study of AP-SA02, the Company's intravenously administered multi-phage product candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia ("SAB") caused by methicillin-sensitive S.

Coll…

Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.